{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:32Z","timestamp":1786982132929,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>During recent years, there has been a growing interest in GABAergic alterations in parkinsonian disorders. This paper aims to review the latest literature published, focusing on in vivo neuroimaging, and to suggest potential future avenues of research in the field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>A growing number of neuroimaging studies have focused on the association with different symptoms of Parkinson\u2019s disease, thereby suggesting a GABAergic role in motor symptoms, gait disturbances, frontal cognition, somatic symptom disorder, and hallucinations. However, there are a number of conflicting results, and further investigations in larger, clinically well-defined cohorts are needed to elucidate possible correlations. In progressive supranuclear palsy, recent evidence suggests a decrease of GABA in the frontal lobe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>In this narrative review, we discuss the possible GABAergic role in the symptoms of PD and atypical parkinsonisms and outline possible research strategies for future neuroimaging of GABAergic changes in parkinsonian disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11910-022-01245-z","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T14:03:36Z","timestamp":1668780216000},"page":"867-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Molecular Imaging of the GABAergic System in Parkinson\u2019s Disease and Atypical Parkinsonisms"],"prefix":"10.1007","volume":"22","author":[{"given":"Miriam H.","family":"Terkelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S.","family":"Hvingelby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pavese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"12","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-016-3464-8","volume":"43","author":"F Niccolini","year":"2016","unstructured":"Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. Eur J Nucl Med Mol Imaging. 2016;43(12):2244\u201354. https:\/\/doi.org\/10.1007\/s00259-016-3464-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1245_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-x","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366\u201375. https:\/\/doi.org\/10.1016\/0166-2236(89)90074-x.","journal-title":"Trends Neurosci"},{"key":"1245_CR3","unstructured":"Purves D AG, Fitzpatrick D, Hall WC, LaMantia AS, Mooney RD, Platt ML, White LE. Neuroscience. Neuroscience. 2018;85\u2013402."},{"key":"1245_CR4","doi-asserted-by":"publisher","unstructured":"Andersson JD MD, Finnema SJ. Positron emission tomography imaging of the \u03b3-aminobutyric acid system. Neurosci Lett. 2019;35\u201343. https:\/\/doi.org\/10.1016\/j.neulet.2018.08.010.","DOI":"10.1016\/j.neulet.2018.08.010"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.wneu.2022.05.121","volume":"165","author":"JM Diamond","year":"2022","unstructured":"Diamond JM, Lopes MB, Elias WJ, Jansen LA. Gamma-aminobutyric acid A receptor subunit expression and cellular localization in the human parkinsonian globus pallidus. World Neurosurg. 2022;165:e159\u201368. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.121.","journal-title":"World Neurosurg"},{"issue":"3","key":"1245_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/mds.10343","volume":"18","author":"F Calon","year":"2003","unstructured":"Calon F, Morissette M, Rajput AH, Hornykiewicz O, B\u00e9dard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord. 2003;18(3):241\u201353. https:\/\/doi.org\/10.1002\/mds.10343.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"1245_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0022-510x(90)90023-g","volume":"100","author":"PD Griffiths","year":"1990","unstructured":"Griffiths PD, Sambrook MA, Perry R, Crossman AR. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson\u2019s disease. J Neurol Sci. 1990;100(1\u20132):131\u20136. https:\/\/doi.org\/10.1016\/0022-510x(90)90023-g.","journal-title":"J Neurol Sci"},{"key":"1245_CR8","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Takashima H, Terada T, Bunai T, Matsudaira T, Obi T, Ouchi Y. In vivo illustration of altered dopaminergic and GABAergic systems in early Parkinson\u2019s disease. Front Neurol. 2022;13:880407. https:\/\/doi.org\/10.3389\/fneur.2022.880407. This study by Takashima and colleagues is, to the best of their knowlegde, the first to use PET imaging to investigate GABAergic alterations in Parkinson's disease. They show reduced binding potential of C11-FMZ in the striatum and cortical areas. Furthermore, they characterize the cognital integrity of their cohort with scores FAB and MMSE and thereby report a positive correlation between excecutive function and GABA in the frontal cortex.","DOI":"10.3389\/fneur.2022.880407"},{"issue":"4","key":"1245_CR9","first-page":"391","volume":"33","author":"K Kawabata","year":"1996","unstructured":"Kawabata K, Tachibana H, Sugita M, Fukuchi M. Impairment of benzodiazepine receptor in Parkinson\u2019s disease evaluated by 123I-iomazenil SPECT. Kaku Igaku. 1996;33(4):391\u20137.","journal-title":"Kaku Igaku"},{"key":"1245_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuroimage.2012.12.004","volume":"86","author":"PG Mullins","year":"2014","unstructured":"Mullins PG, McGonigle DJ, O\u2019Gorman RL, Puts NA, Vidyasagar R, Evans CJ, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2014;86:43\u201352. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.12.004.","journal-title":"Neuroimage"},{"key":"1245_CR11","doi-asserted-by":"publisher","unstructured":"\u2022 Seger AD, Farrher E, Doppler CEJ, Gogishvili A, Worthoff WA, Filss CP, et al. Putaminal y-aminobutyric acid modulates motor response to dopaminergic therapy in Parkinson\u2019s disease. Mov Disord. 2021;36(9):2187\u201392. https:\/\/doi.org\/10.1002\/mds.28674. The authors use 7-T MRS to investigate the GABAergic signal in the putamen patients with Parkinson\u2019s disease and find it increased compared to healthy controls. They assess their patients clinically with the MDS-UPDRS before and after dopaminergic therapy and find an inverse correlation between putaminal GABA levels and treatment response.","DOI":"10.1002\/mds.28674"},{"issue":"1","key":"1245_CR12","doi-asserted-by":"publisher","first-page":"e30918","DOI":"10.1371\/journal.pone.0030918","volume":"7","author":"UE Emir","year":"2012","unstructured":"Emir UE, Tuite PJ, \u00d6z G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS ONE. 2012;7(1):e30918. https:\/\/doi.org\/10.1371\/journal.pone.0030918.","journal-title":"PLoS ONE"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fneur.2018.00806","volume":"9","author":"RL O\u2019Gorman Tuura","year":"2018","unstructured":"O\u2019Gorman Tuura RL, Baumann CR, Baumann-Vogel H. Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. Front Neurol. 2018;9:806. https:\/\/doi.org\/10.3389\/fneur.2018.00806.","journal-title":"Front Neurol"},{"issue":"1","key":"1245_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.410200106","volume":"20","author":"SJ Kish","year":"1986","unstructured":"Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, Shannak K, et al. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson\u2019s disease: correlation with striatal dopamine loss. Ann Neurol. 1986;20(1):26\u201331. https:\/\/doi.org\/10.1002\/ana.410200106.","journal-title":"Ann Neurol"},{"issue":"6","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/nbm.1504","volume":"23","author":"C Chassain","year":"2010","unstructured":"Chassain C, Bielicki G, Keller C, Renou JP, Durif F. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed. 2010;23(6):547\u201353. https:\/\/doi.org\/10.1002\/nbm.1504.","journal-title":"NMR Biomed"},{"issue":"3","key":"1245_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1471-4159.2007.05185.x","volume":"105","author":"C Chassain","year":"2008","unstructured":"Chassain C, Bielicki G, Durand E, Lolignier S, Essafi F, Traor\u00e9 A, et al. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson\u2019s disease, the MPTP-intoxicated mouse. J Neurochem. 2008;105(3):874\u201382. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05185.x.","journal-title":"J Neurochem"},{"issue":"3","key":"1245_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11604-017-0714-z","volume":"36","author":"EEA Elmaki","year":"2018","unstructured":"Elmaki EEA, Gong T, Nkonika DM, Wang G. Examining alterations in GABA concentrations in the basal ganglia of patients with Parkinson\u2019s disease using MEGA-PRESS MRS. Jpn J Radiol. 2018;36(3):194\u20139. https:\/\/doi.org\/10.1007\/s11604-017-0714-z.","journal-title":"Jpn J Radiol"},{"issue":"6","key":"1245_CR18","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/jmri.25865","volume":"47","author":"T Gong","year":"2018","unstructured":"Gong T, Xiang Y, Saleh MG, Gao F, Chen W, Edden RAE, et al. Inhibitory motor dysfunction in parkinson\u2019s disease subtypes. J Magn Reson: JMRI. 2018;47(6):1610\u20135. https:\/\/doi.org\/10.1002\/jmri.25865.","journal-title":"J Magn Reson: JMRI"},{"key":"1245_CR19","doi-asserted-by":"publisher","unstructured":"Pesch B, Casjens S, Woitalla D, Dharmadhikari S, Edmondson DA, Zella MAS, et al. Impairment of motor function correlates with neurometabolite and brain iron alterations in Parkinson\u2019s disease. Cells. 2019;8(2). https:\/\/doi.org\/10.3390\/cells8020096.","DOI":"10.3390\/cells8020096"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroimage.2015.06.066","volume":"120","author":"S Dharmadhikari","year":"2015","unstructured":"Dharmadhikari S, Ma R, Yeh CL, Stock AK, Snyder S, Zauber SE, et al. Striatal and thalamic GABA level concentrations play differential roles for the modulation of response selection processes by proprioceptive information. Neuroimage. 2015;120:36\u201342. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.06.066.","journal-title":"Neuroimage"},{"issue":"14 Sepplement","key":"1245_CR21","doi-asserted-by":"crossref","first-page":"6.076","DOI":"10.1212\/WNL.84.14_supplement.P6.076","volume":"84","author":"S Zauber","year":"2015","unstructured":"Zauber S, Dharmadhikari S, Snyder S, Dydak U. Elevated thalamic GABA levels in Parkinson disease, measured by 3 tesla MR spectroscopy, correlate with disease severity (P6076). Neurology. 2015;84(14 Sepplement):6.076.","journal-title":"Neurology."},{"key":"1245_CR22","doi-asserted-by":"publisher","unstructured":"\u2022 van Nuland AJM, den Ouden HEM, Zach H, Dirkx MFM, van Asten JJA, Scheenen TWJ, et al. GABAergic changes in the thalamocortical circuit in Parkinson\u2019s disease. Hum Brain Mapp. 2020;41(4):1017\u201329. https:\/\/doi.org\/10.1002\/hbm.24857. Unlike the majority of studies discussed in the present review, the authors present data from a larger cohort of 60 patients with Parkinson's disease and 22 healthy controls. This allows them to divide patients according to tremor sympthomatology and treatment response. They found no differences in GABA levels between patients and healthy controls; however, they did find an inverse correlation between GABA levels in the motor cortes and MDS-UPDRS motor scores and, furthermore, in tremor-dominant patients, a similar negative correlation in the thalamus.","DOI":"10.1002\/hbm.24857"},{"issue":"12","key":"1245_CR23","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/mds.28221","volume":"35","author":"S Delli Pizzi","year":"2020","unstructured":"Delli Pizzi S, Franciotti R, Ferretti A, Edden RAE, Z\u00f6llner HJ, Esposito R, et al. High \u03b3-aminobutyric acid content within the medial prefrontal cortex is a functional signature of somatic symptoms disorder in patients with Parkinson\u2019s disease. Mov Disord. 2020;35(12):2184\u201392. https:\/\/doi.org\/10.1002\/mds.28221.","journal-title":"Mov Disord"},{"issue":"1","key":"1245_CR24","doi-asserted-by":"publisher","first-page":"e84081","DOI":"10.1371\/journal.pone.0084081","volume":"9","author":"A Gr\u00f6ger","year":"2014","unstructured":"Gr\u00f6ger A, Kolb R, Sch\u00e4fer R, Klose U. Dopamine reduction in the substantia nigra of Parkinson\u2019s disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLoS ONE. 2014;9(1):e84081. https:\/\/doi.org\/10.1371\/journal.pone.0084081.","journal-title":"PLoS ONE"},{"issue":"2","key":"1245_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mrm.20761","volume":"55","author":"G Oz","year":"2006","unstructured":"Oz G, Terpstra M, Tk\u00e1c I, Aia P, Lowary J, Tuite PJ, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med. 2006;55(2):296\u2013301. https:\/\/doi.org\/10.1002\/mrm.20761.","journal-title":"Magn Reson Med"},{"issue":"5","key":"1245_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10334-021-00910-7","volume":"34","author":"Y Song","year":"2021","unstructured":"Song Y, Gong T, Saleh MG, Mikkelsen M, Wang G, Edden RAE. Upper brainstem GABA levels in Parkinson\u2019s disease. MAGMA. 2021;34(5):689\u201396. https:\/\/doi.org\/10.1007\/s10334-021-00910-7.","journal-title":"MAGMA"},{"issue":"1","key":"1245_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2011.08.013","volume":"18","author":"SR Romenets","year":"2012","unstructured":"Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012;18(1):54\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.08.013.","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"1245_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"1245_CR29","doi-asserted-by":"publisher","unstructured":"Piras F, Vecchio D, Assogna F, Pellicano C, Ciullo V, Banaj N, et al. Cerebellar GABA levels and cognitive interference in Parkinson\u2019s disease and healthy comparators. J Pers Med. 2020;11(1). https:\/\/doi.org\/10.3390\/jpm11010016.","DOI":"10.3390\/jpm11010016"},{"issue":"7","key":"1245_CR30","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1212\/wnl.0000000000006007","volume":"91","author":"MJ Firbank","year":"2018","unstructured":"Firbank MJ, Parikh J, Murphy N, Killen A, Allan CL, Collerton D, et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology. 2018;91(7):e675\u201385. https:\/\/doi.org\/10.1212\/wnl.0000000000006007.","journal-title":"Neurology"},{"issue":"1","key":"1245_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40478-016-0334-3","volume":"4","author":"AA Khundakar","year":"2016","unstructured":"Khundakar AA, Hanson PS, Erskine D, Lax NZ, Roscamp J, Karyka E, et al. Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathol Commun. 2016;4(1):66. https:\/\/doi.org\/10.1186\/s40478-016-0334-3.","journal-title":"Acta Neuropathol Commun"},{"key":"1245_CR32","doi-asserted-by":"publisher","first-page":"117309","DOI":"10.1016\/j.jns.2021.117309","volume":"422","author":"Y Song","year":"2021","unstructured":"Song Y, Gong T, Xiang Y, Mikkelsen M, Wang G, Edden RAE. Single-dose L-dopa increases upper brainstem GABA in Parkinson\u2019s disease: a preliminary study. J Neurol Sci. 2021;422:117309. https:\/\/doi.org\/10.1016\/j.jns.2021.117309.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1245_CR33","doi-asserted-by":"publisher","first-page":"e01239","DOI":"10.1002\/brb3.1239","volume":"9","author":"A M\u00f8ller","year":"2019","unstructured":"M\u00f8ller A, R\u00f8mer Thomsen K, Brooks DJ, Mouridsen K, Blicher JU, Hansen KV, et al. Attenuation of dopamine-induced GABA release in problem gamblers. Brain Behav. 2019;9(3):e01239. https:\/\/doi.org\/10.1002\/brb3.1239.","journal-title":"Brain Behav"},{"issue":"6","key":"1245_CR34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1523\/jneurosci.2028-18.2018","volume":"39","author":"EF Lopes","year":"2019","unstructured":"Lopes EF, Roberts BM, Siddorn RE, Clements MA, Cragg SJ. Inhibition of nigrostriatal dopamine release by striatal GABA(A) and GABA(B) receptors. J Neurosci. 2019;39(6):1058\u201365. https:\/\/doi.org\/10.1523\/jneurosci.2028-18.2018.","journal-title":"J Neurosci"},{"issue":"7419","key":"1245_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature11466","volume":"490","author":"NX Tritsch","year":"2012","unstructured":"Tritsch NX, Ding JB, Sabatini BL. Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature. 2012;490(7419):262\u20136. https:\/\/doi.org\/10.1038\/nature11466.","journal-title":"Nature"},{"issue":"1","key":"1245_CR36","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1038\/s41467-020-18247-5","volume":"11","author":"BM Roberts","year":"2020","unstructured":"Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, et al. GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat Commun. 2020;11(1):4958. https:\/\/doi.org\/10.1038\/s41467-020-18247-5.","journal-title":"Nat Commun"},{"issue":"1","key":"1245_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41531-022-00298-8","volume":"8","author":"P Trujillo","year":"2022","unstructured":"Trujillo P, Song AK, Hay KR, Aumann M, Yan Y, Kang H, et al. Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients. NPJ Parkinsons Dis. 2022;8(1):37. https:\/\/doi.org\/10.1038\/s41531-022-00298-8.","journal-title":"NPJ Parkinsons Dis"},{"key":"1245_CR38","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Adams NE, Hughes LE, Rouse MA, Phillips HN, Shaw AD, Murley AG, et al. GABAergic cortical network physiology in frontotemporal lobar degeneration. Brain: a journal of neurology. 2021;144(7):2135\u201345. https:\/\/doi.org\/10.1093\/brain\/awab097. \u2022\u2022 The authors report, to the best of their knowlegde, the first use of 7-T MRS to detect GABAergic changes in patient with progressive supranuclear palsy. They find decreased levels in the frontal cortex compared to healthy controls, which is consistent with previos PET imaging findings by Foster and colleagues.","DOI":"10.1093\/brain\/awab097"},{"issue":"4","key":"1245_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.neurol.2017.03.007","volume":"173","author":"C Bonnet","year":"2017","unstructured":"Bonnet C, Rusz J, Hanu\u0161ka J, Dezortov\u00e1 M, J\u00edr\u016f F, Sieger T, et al. GABA spectra and remote distractor effect in progressive supranuclear palsy: a pilot study. Rev Neurol (Paris). 2017;173(4):225\u20139. https:\/\/doi.org\/10.1016\/j.neurol.2017.03.007.","journal-title":"Rev Neurol (Paris)"},{"issue":"9","key":"1245_CR40","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/wnl.54.9.1768","volume":"54","author":"NL Foster","year":"2000","unstructured":"Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology. 2000;54(9):1768\u201373. https:\/\/doi.org\/10.1212\/wnl.54.9.1768.","journal-title":"Neurology"},{"issue":"2","key":"1245_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/jpd-130301","volume":"4","author":"W Schrempf","year":"2014","unstructured":"Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson\u2019s disease. J Parkinsons Dis. 2014;4(2):211\u201321. https:\/\/doi.org\/10.3233\/jpd-130301.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1245_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/sleep\/31.3.342","volume":"31","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, Lyoo IK, Lee YS, Sung YH, Kim HJ, Kim JH, et al. Increased GABA levels in medial prefrontal cortex of young adults with narcolepsy. Sleep. 2008;31(3):342\u20137. https:\/\/doi.org\/10.1093\/sleep\/31.3.342.","journal-title":"Sleep"},{"issue":"12","key":"1245_CR43","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov Disord. 2015;30(12):1600\u201311. https:\/\/doi.org\/10.1002\/mds.26431.","journal-title":"Mov Disord"},{"issue":"19","key":"1245_CR44","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1523\/jneurosci.0347-11.2011","volume":"31","author":"PL Brooks","year":"2011","unstructured":"Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31(19):7111\u201321. https:\/\/doi.org\/10.1523\/jneurosci.0347-11.2011.","journal-title":"J Neurosci"},{"issue":"1","key":"1245_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.sleep.2012.09.009","volume":"14","author":"R Ferri","year":"2013","unstructured":"Ferri R, Marelli S, Ferini-Strambi L, Oldani A, Colli F, Schenck CH, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2012.09.009.","journal-title":"Sleep Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01245-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01245-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01245-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T22:49:22Z","timestamp":1728427762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01245-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01245-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"21 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Miriam H. Terkelsen, Victor S. Hvingelby, and Nicola Pavese each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}